Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 33 Thyroid Neoplasms 9 Neoplasms 8 Thyroid Carcinoma, Anaplastic 7 Thyroid Cancer, Papillary 4 Neoplasm Metastasis 4 Multiple Myeloma 4 Colorectal Neoplasms 4 Ameloblastoma 4 Hematologic Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Brain Neoplasms 3 Skin Neoplasms 2 Lymphoma, Non-Hodgkin 2 Glioma 2 Adenocarcinoma, Follicular 2 Unspecified Adult Solid Tumor, Protocol Specific 1 Thyroid cancer, follicular 1 Thyroid cancer, Hurthle cell 1 Thrombocytosis 1 Spinocerebellar Degenerations 1 Solid Tumor 1 Sexual Dysfunction, Physiological 1 Rare Malignant Neoplasm 1 Prostatic Neoplasms 1 Primary Myelofibrosis 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neoplasms by Site 1

Interventions

trametinib 1 ofatumumab 1 liposomal amphotericin B 1 dabrafenib 1 Surveys and Questionnaires 1 Ritonavir 1 Quality of Life 1 Povidone-Iodine 1 Metformin 1 Meropenem 1 Lenalidomide 1 Daptomycin 1 Cloxacillin 1 Ciprofloxacin 1 Cilastatin, Imipenem Drug Combination 1 Ceftazidime 1 Cefepime 1 Caspofungin 1 Anti-Bacterial Agents 1 Amoxicillin 1 Amikacin 1 Administration, Intravesical 1 Acetaminophen 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Fever × dabrafenib × Clear all

NCT01972347 2025-12-16

Neo Combi

Melanoma Institute Australia

Phase 2 Active not recruiting

Fever, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡